TriangleAtezolizumab (NCT05333458)
Atezolizumab trial for Advanced Alveolar Soft Part Sarcoma (NCT05333458). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for people aged twelve or older with unresectable, metastatic alveolar soft part sarcoma that progressed after checkpoint immunotherapy. This is the main efficacy cohort; a separate safety group permits other advanced soft-tissue sarcomas.
The idea: combine atezolizumab infusions with selinexor tablets. Atezolizumab blocks PD-L1 immune suppression. Selinexor blocks nuclear export, retaining growth-control proteins inside cell nuclei. Researchers measure tumor responses. Adult research biopsies are planned, with safety exceptions.
This phase 2 study plans 27 patients. A P Chen leads eleven recruiting US sites for the National Cancer Institute.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.